PATENT COOPERATION TREATY

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference EX04-057C-PC	FOR FURTHER ACTION	See item 4 below			
International application No. PCT/US2004/026338	International filing date (day/month/year) 12 August 2004 (12.08.2004)	Priority date (day/month/year) 14 August 2003 (14.08.2003)			
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237					
Applicant EXELIXIS, INC.					

1.	 This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a). 					
2.	This REPORT consists of a total	l of 4 sheets, including this of	cover sheet.			
	In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.					
3.	3. This report contains indications relating to the following items:					
	Box No. I Basis of the report					
	Box No. II Priority					
	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability				
	Box No. IV	Lack of unity of invention				
	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
	Box No. VI	Certain documents cited				
	Box No. VII	Certain defects in the international application				
	Box No. VIII	Certain observations on the international application				
4.	4. The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis .2).					
			Date of issuance of this report 07 June 2006 (07.06.2006)			
The International Bureau of WIPO 34, chemin des Colombettes		ombettes	Authorized officer Nora Lindner			
 Facsir	1211 Geneva 20, Sv nile No. +41 22 740 14 35	vitzeriand	Telephone No. +41 22 338 89 65			
Form I	orm PCT/IR/373 (January 2004)					

PATENT COOPERATION TREATY

REC'D	1	2	MAY	2006
WIFO				PCT

From the						NAME O		
INTERNATIONAL SEARCHING AUTHORITY					WIFO			
To: LALEH SHAYESTEH 170 HARBOR WAY			PCT					
P.O. BOX 511 SOUTH SAN FRANCISCO, CA 94083-0511			WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY					
						(PCT Rule 43bis.1)		
					Date of mailing	4.0.77.0000		
Applicant's	s or agent's file r	eference			FOR FURTHER ACTION 10 MAY 2006			
EX04-0570					See paragraph 2 below			
Internation	al application No).	International filing	date	(day/month/year)	Priority date (day/month/year)		
PCT/US04		(700)	12 August 2004 (1			14 August 2003 (14.08.2003)		
Internation	al Patent Classifi	cation (IPC) or	both national class	sificat	ion and IPC			
	7K 16/40; C12Q	1/00 and US C	cl.: 435/4, 7.23,					
Applicant								
ELELIXIS								
1. This of	pinion contains in	ndications relat	ing to the following	g item	s:			
\boxtimes	Box No. I	Basis of the c	pinion					
	Box No. II	Priority						
	Box No. III	Non-establish	unent of opinion w	ith reg	gard to novelty, inve	entive step and industrial applicability		
	Box No. IV	Lack of unity	of invention					
\boxtimes	Box No. V				l(a)(i) with regard to s supporting such s	to novelty, inventive step or industrial statement		
	Box No. VI	Certain docur	nents cited			İ		
	Box No. VII	Certain defec	ts in the internation	onal application				
	Box No. VIII	Certain obser	vations on the inter	nation	al application			
2. FURT	HER ACTION	N						
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.								
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.								
For further options, see Form PCT/ISA/220.								
3. For furt	ther details, see n	otes to Form P	CT/ISA/220.			1		
Name and n	nailing address o	f the ISA/ US	Date of co	mplet	ion of this opinion	Authorized officer		
Ma	ail Stop PCT, Attn:	ISA/US				Jeffey Siew Juan		
Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450				105 (20.03.2003)	Telephone No. 571 272 1600			
711	Alexandria, Virginia 22313-1450 Telephone No. 571-272-1600							

P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (703) 305-3230
Form PCT/ISA/237 (cover sheet) (April 2005)

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/US04/26338

Box N	o. I Basis of this opinion
1. With	regard to the language, this opinion has been established on the basis of:
\boxtimes	the international application in the language in which it was filed
	a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed tion, this opinion has been established on the basis of:
a.	type of material
	a sequence listing
	table(s) related to the sequence listing
b.	format of material
	on paper
	in electronic form
c.	time of filing/furnishing
	contained in the international application as filed.
	filed together with the international application in electronic form.
	furnished subsequently to this Authority for the purposes of search.
3. 🔲	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additi	onal comments:
	•

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US04/26338

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement 1. Statement				
	Claims NONE	NO		
Inventive step (IS)	Claims NONE	YES		
	Claims 1-25	NO		
Industrial applicability (IA)	Claims NONE	YES		
•	Claims NONE	NO		

2. Citations and explanations:

Claims 1-25 lack inventive under PCT Article 33(3) as being obvious over Bienz et al., (US Patent Application Publication, US2002/0015943) in view of Chen et al., (Lab Invest, vol 59, page 453, 1988) and Monga et al., (Gastroenterology, vol 124, page 202-16, Jan, 2003).

Bienz et al., teach a method of identifying a modulator in β -catenin pathway comprising an assay system of binding polypeptide of β -catenin, APC. Bienz et al., teach that the test compound to modulate binding may be determined by determine the binding of β -catenin polypeptide and APC polypeptide in the presence or absence of the test compound (para 11-17 and 45). Bienz et al., also teach the assay system in cell line comprising APC or β catenin truncation or mutation, which results in defective beta catenin function (para 38 and 103-104). Bienz et al., also teach that test compound could be antibody, peptide, nucleic acid, small molecule, which can be used in vitro cell system or administration to the individual (para 72).

Chen et al., a synthetic inhibitor of arylsulfase, Sodium 2-hydrozy-5-alpha-toluenesulfonated (HNT) inhibit specifically the growth of capillary blood vessels and potentiate antiangiogenic activity when the concentration of heparin was suboptimal.

Monga et al., teach a phosphorodiamidate morpholino ligomer (PMO) antisense to beta-catenin, which effectively inhibits synthesis of its protein and modulate cell proliferation and apoptosis for the cells (abstract).

It would have been prima facie obvious to one of ordinary skill in the art at the time the claimed invention was made to use the method of identifying a modulator in β -catenin pathway taught by Bienz et al., comprising arylsulfatase inhibitor of Chen et al's and PMO antisense of Monga et al.'s teachings. One of ordinary skill in the art would have been motivated with a reasonable expectation of success to apply the teachings of Chen et al., and Monga et al., to the teaching of Bienz et al., to use the method of identifying a modulator in β -catenin pathway because Bienz et al., have shown a method of identifying a modulator, Chen has shown HNT as a sulfatase inhibitor, which modulate the activity of sulfatase and Monga et al., have shown PMO antisense for-catenin.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US04/26338

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C07K 16/40; C12Q 1/00 US CL : 435/4, 7.23,						
According to I	International Patent Classification (IPC) or to both nat	onal classification and	1 IPC			
	S SEARCHED					
Minimum doc U.S. : 435	umentation searched (classification system followed b 5/4, 7.23,	classification symbo	ls)			
Documentation	Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)						
C. DOCU	MENTS CONSIDERED TO BE RELEVANT					
Category *	Citation of document, with indication, where a	propriate, of the relev	ant passages	Relevant to claim No.		
Y	Bienz et al., US Patent Application Publication, US2	02/0015943.		1-25		
Y				1-25		
•	Chen et al., Lab Invest, vol 59, page 453, 1988					
Y	Monga et al., Gastroenterology, vol 124, page 202-16	, Jan, 2003	Ì	1-25		
				•		
, I						
ĺ						
]			
ŀ						
			1			
Further	documents are listed in the continuation of Box C.		family annex.			
• Sp	ecial categories of cited documents:	"T" later docume	nt published after the inter	national filing date or priority tion but cited to understand the		
"A" document	defining the general state of the art which is not considered to be of		theory underlying the inven			
particular 1		"X" document of	particular relevance; the c	laimed invention cannot be		
Ť.	lication or patent published on or after the international filing date		ovel or cannot be consider cument is taken alone	ed to involve an inventive step		
"L" document	which may throw doubts on priority claim(s) or which is cited to be publication date of another citation or other special reason (as	"Y" document of	particular relevance; the c	laimed invention cannot be		
specified)	to publication date of another chaden of outer apostar course (considered to	ith one or more other such	when the document is documents, such combination		
"O" document	referring to an oral disclosure, use, exhibition or other means		is to a person skilled in the			
"P" document published prior to the international filing date but later than the "&" document member of the same patent family						
priority date claimed						
Date of the ac	tual completion of the international search	Date of mailing of th	e international search	report		
26 September	26 September 2005 (26.09.2005)					
Name and mai	iling address of the ISA/US	Authorized	va Illa	lopes		
	Stop PCT, Attn: ISA/US missioner for Patents	Jeffrey Siev	H			
PO	P.O. Box 1450					
Alexandria, Virginia 22313-1450						

Facsimile No. (703) 305-3230
Form PCT/ISA/210 (second sheet) (April 2005)